Abstract
Intrathecal enzyme replacement therapy has been proposed to treat central nervous system (CNS) disease due to mucopolysaccharidosis type I. Our research has shown that repeated injections of recombinant enzyme into the spinal fluid corrects enzyme deficiency and normalizes lysosomal storage in the canine model. The challenge is to translate the success in the animal where there are fewer study limitations to human patients where studies are more restricted. This review will explore what is known about the measurement of clinically-relevant outcomes of intrathecal enzyme replacement therapy for MPS I (including ongoing clinical trials), the challenges in translating therapies for the CNS in rare diseases, and new outcome measures that could aid translation of CNS therapies for MPS disorders.
Keywords: Enzyme replacement therapy, hurler, intrathecal, lysosomal storage disease, mucopolysaccharidosis, CNS, spinal fluid, clinically-relevant outcomes, MPS I, CNS therapies, MPS disorders, lysosomal hydrolase alpha-L-iduronidase, leukocyte enzymatic assays, hydrocephalus and spinal cord compression, ventriculoperitoneal shunt
Current Pharmaceutical Biotechnology
Title: Intrathecal Enzyme Replacement Therapy for Mucopolysaccharidosis I: Translating Success in Animal Models to Patients
Volume: 12 Issue: 6
Author(s): Patricia I. Dickson and Agnes H. Chen
Affiliation:
Keywords: Enzyme replacement therapy, hurler, intrathecal, lysosomal storage disease, mucopolysaccharidosis, CNS, spinal fluid, clinically-relevant outcomes, MPS I, CNS therapies, MPS disorders, lysosomal hydrolase alpha-L-iduronidase, leukocyte enzymatic assays, hydrocephalus and spinal cord compression, ventriculoperitoneal shunt
Abstract: Intrathecal enzyme replacement therapy has been proposed to treat central nervous system (CNS) disease due to mucopolysaccharidosis type I. Our research has shown that repeated injections of recombinant enzyme into the spinal fluid corrects enzyme deficiency and normalizes lysosomal storage in the canine model. The challenge is to translate the success in the animal where there are fewer study limitations to human patients where studies are more restricted. This review will explore what is known about the measurement of clinically-relevant outcomes of intrathecal enzyme replacement therapy for MPS I (including ongoing clinical trials), the challenges in translating therapies for the CNS in rare diseases, and new outcome measures that could aid translation of CNS therapies for MPS disorders.
Export Options
About this article
Cite this article as:
I. Dickson Patricia and H. Chen Agnes, Intrathecal Enzyme Replacement Therapy for Mucopolysaccharidosis I: Translating Success in Animal Models to Patients, Current Pharmaceutical Biotechnology 2011; 12 (6) . https://dx.doi.org/10.2174/138920111795542642
DOI https://dx.doi.org/10.2174/138920111795542642 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Endothelial Primary Cilia: Mechanosensation and Hypertension
Current Hypertension Reviews Neurosarcoidosis
Current Neuropharmacology Electroconvulsive Therapy in Child and Adolescent Psychiatry
Current Psychiatry Reviews Antioxidant SkQ1 Alleviates Signs of Alzheimer’s Disease-like Pathology in Old OXYS Rats by Reversing Mitochondrial Deterioration
Current Alzheimer Research Magnetic Resonance Elastography
Current Medical Imaging Dural Venous Sinuses: What We Need to Know
Current Medical Imaging The Synthesis and Evaluation of Novel Lactate Dehydrogenase Nanobioconjugates
Current Nanoscience Application of NMR to the Study of Cells and Body Fluids
Current Organic Chemistry High Dose Zolpidem Induced Fetal Neural Tube Defects
Current Drug Safety Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets
Current Neuropharmacology Differentiating the Dementias. Revisiting Synucleinopathies and Tauopathies
Current Alzheimer Research Iron Overload is Associated with Perihematoma Edema Growth Following Intracerebral Hemorrhage that may Contribute to In-hospital Mortality and Long-term Functional Outcome
Current Neurovascular Research Complications of Otitis Media
Infectious Disorders - Drug Targets The Differential Diagnostic Value of the Callosal Angle and Evans Index in Mild Cognitive Impairment and Alzheimer's Disease
Current Medical Imaging Geriatric Depression - Review for Primary Care
Current Psychiatry Reviews Quality and Safety in Pediatric Complex Care
Current Pediatric Reviews Cerebrospinal Fluid, Brain Electrolytes Balance, and the Unsuspected Intrinsic Property of Melanin to Dissociate the Water Molecule
CNS & Neurological Disorders - Drug Targets The “Aged Garlic Extract” (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD)
Current Medicinal Chemistry The Insulin-like Growth Factor-1 Axis and its Potential as a Therapeutic Target in Central Nervous System (CNS) Disorders
Central Nervous System Agents in Medicinal Chemistry Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?
Current Pharmaceutical Design